Viemed Healthcare (VMD) CMO Frazier logs RSU vesting and share withholding

Rhea-AI Filing Summary

Viemed Healthcare Chief Medical Officer reports equity award vesting and related share transactions. Director and Chief Medical Officer William Frazier reported the vesting of 3,401 Restricted Stock Units (each equal to one common share) and 850 cash-settled phantom share units on January 21, 2026. After these transactions, he directly owned 71,682 common shares.

To cover tax obligations from the RSU vesting, 1,169 common shares were withheld by the company at a per‑share value of $7.49, and 850 common shares were simultaneously acquired and disposed of in connection with settlement of phantom share units for cash. Following the derivative activity, he held 6,800 Restricted Stock Units and 1,700 phantom share units, which were originally granted on January 21, 2025 and vest in three equal annual installments.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Frazier William

(Last) (First) (Middle)

625 E. KALISTE SALOOM RD.

(Street)

LAFAYETTE LA 70508

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VIEMED HEALTHCARE, INC. [ VMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	01/21/2026		M		3,401	A	(1)	72,851	D
Common Shares	01/21/2026		F		1,169(2)	D	$7.49(3)	71,682	D
Common Shares	01/21/2026		M		850	A	(4)	72,532	D
Common Shares	01/21/2026		D		850	D	$7.49(3)	71,682	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/21/2026		M			3,401	(5)	01/21/2028	Common Shares	3,401	$0	6,800	D
Phantom Share Units	(4)	01/21/2026		M			850	(6)	01/21/2028	Common Shares	850	(4)	1,700	D

Explanation of Responses:

1. Each Restricted Stock Unit (RSU) represents a contingent right to receive one common share.

2. Shares that were withheld by the issuer to satisfy the reporting person's tax obligation resulting from the vesting of restricted stock units.

3. Per share value is based on the market closing price of the common shares for January 21, 2026.

4. Represents vesting of cash-settled phantom shares granted under the Issuer's Phantom Share Unit Plan. Each phantom share is the economic equivalent of one Company common share. The settlement of the phantom shares for cash is reported on this Form 4 as a disposition of the phantom shares being settled in exchange for the acquisition of the underlying Company common shares, and a simultaneous disposition of the underlying Company common shares to the Company for cash.

5. Restricted Stock Units (RSUs) granted to reporting person on January 21, 2025, which vest in three equal annual installments beginning on the first anniversary of the grant date.

6. Represents an award granted on January 21, 2025 under the Issuer's Phantom Share Unit Plan which vests in three equal annual installments beginning on the first anniversary of the grant date.

Remarks:

	/s/ Jesse Bergeron, Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Viemed Healthcare (VMD) report for William Frazier?

The filing shows that William Frazier, a director and Chief Medical Officer of Viemed Healthcare, reported vesting of equity awards and related common share transactions on January 21, 2026, including Restricted Stock Units, phantom share units, and associated share withholding for taxes.

How many Viemed Healthcare (VMD) common shares does William Frazier hold after the reported transactions?

After the transactions on January 21, 2026, William Frazier beneficially owned 71,682 common shares of Viemed Healthcare, held directly.

What Restricted Stock Unit activity was disclosed for Viemed Healthcare (VMD) in this Form 4?

The Form 4 reports that 3,401 Restricted Stock Units vested and were converted into an equal number of common shares on January 21, 2026. Each RSU represents a contingent right to receive one common share. After this transaction, Frazier held 6,800 RSUs, from a grant made on January 21, 2025 that vests in three equal annual installments.

Why were some Viemed Healthcare (VMD) shares withheld in William Frazier’s Form 4 filing?

The filing explains that 1,169 common shares were withheld by Viemed Healthcare to satisfy William Frazier’s tax obligation arising from the vesting of Restricted Stock Units. The per share value used was $7.49, based on the market closing price of the common shares on January 21, 2026.

What are the phantom share units reported for Viemed Healthcare (VMD) and how were they settled?

The Form 4 reports 850 phantom share units vesting under Viemed Healthcare’s Phantom Share Unit Plan on January 21, 2026. Each phantom share is the economic equivalent of one common share. The settlement for cash is recorded as a disposition of phantom shares in exchange for acquisition and simultaneous disposition of the underlying common shares. After this, Frazier held 1,700 phantom share units, from an award granted on January 21, 2025 that vests in three equal annual installments.

What roles does William Frazier hold at Viemed Healthcare (VMD) according to this Form 4?

According to the Form 4, William Frazier is both a director and an officer of Viemed Healthcare, serving as the company’s Chief Medical Officer.